vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»10.15690/vsp.v23i5.2806vsp-3611Research ArticleКЛИНИЧЕСКОЕ НАБЛЮДЕНИЕCLINICAL OBSERVATIONSЭффективность устекинумаба при ладонно-подошвенном псориазе у детей: серия клинических случаевUstekinumab Efficacy in Children with Palmoplantar Psoriasis: Case Serieshttps://orcid.org/0000-0001-5739-0941ЛеоноваМ. А.LeonovaMaria A.

Леонова Мария Алексеевна, врач-дерматовенеролог отделения дерматологии и аллергологии

119296, Москва, Ломоносовский пр-т, д. 2/62, стр. 1, тел.: +7 (495) 967-14-20

Moscow

dr.maria.leonova@gmail.comhttps://orcid.org/0000-0003-2252-8570МурашкинН. Н.MurashkinNikolay N.

Москва

Moscow

https://orcid.org/0000-0002-6034-8231МатерикинА. И.MaterikinAlexander I.

Москва

Moscow

https://orcid.org/0000-0002-4107-4642ЕпишевР. В.EpishevRoman V.

Москва

Moscow

https://orcid.org/0000-0001-9777-0156ФедоровД. В.FedorovDmitriy V.

Москва

Moscow

https://orcid.org/0000-0002-0858-8780ОпрятинЛ. А.OpryatinLeonid A.

Москва

Moscow

https://orcid.org/0000-0002-0081-0981ИвановР. А.IvanovRoman A.

Москва

Moscow

https://orcid.org/0009-0003-5367-3268ПавловаЕ. С.PavlovaEkaterina S.

Москва

Moscow

НМИЦ здоровья детейРоссияNational Medical Research Center of Children’s HealthRussian FederationНМИЦ здоровья детей; Первый МГМУ им. И.М. Сеченова (Сеченовский Университет); ЦГМА УДП РФРоссияNational Medical Research Center of Children’s Health; Sechenov First Moscow State Medical University; Central State Medical Academy of Department of Presidential AffairsRussian Federation202431102024235370375Copyright © Леонова М.А., Мурашкин Н.Н., Материкин А.И., Епишев Р.В., Федоров Д.В., Опрятин Л.А., Иванов Р.А., Павлова Е.С., 20242024Леонова М.А., Мурашкин Н.Н., Материкин А.И., Епишев Р.В., Федоров Д.В., Опрятин Л.А., Иванов Р.А., Павлова Е.С.Leonova M.A., Murashkin N.N., Materikin A.I., Epishev R.V., Fedorov D.V., Opryatin L.A., Ivanov R.A., Pavlova E.S.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/3611

Обоснование. Пациентам с ладонно-подошвенным псориазом при недостаточной эффективности стандартной наружной терапии, физиотерапевтического лечения, терапии классическими иммуносупрессорами рекомендовано лечение генно-инженерными биологическими препаратами. Нами представлены результаты лечения устекинумабом резистентного к стандартным методам терапии ладонно-подошвенного псориаза у детей. Описание клинического случая. Представлены результаты лечения устекинумабом 12 случаев ладонно-подошвенного псориаза у детей. При проведении дообследования данных за наличие коморбидных патологий у описываемых пациентов выявлено не было, и в связи с отсутствием противопоказаний им была инициирована генно-инженерная биологическая терапия препаратом устекинумаб в дозе 45 мг подкожно согласно рекомендуемой схеме лечения. Через 12 нед после начала терапии устекинумабом у 58,33% детей отмечалось достижение показателя индекса PASI 90. Заключение. Пациентам с ладонно-подошвенным псориазом ввиду системного хронического патологического процесса и поражения функционально значимых зон при недостаточной эффективности стандартной наружной терапии, физиотерапевтического лечения, терапии классическими иммуносупрессорами при отсутствии противопоказаний может быть рекомендовано лечение генно-инженерными биологическими препаратами, в частности устекинумабом, согласно рекомендуемой схеме.

Background. Management with genetically engineered biologic drugs is recommended for patients with palmoplantar psoriasis when standard external therapy, physical therapy, and classical immunosuppressants lack efficacy. We present the results of ustekinumab administration in children with palmoplantar psoriasis resistant to standard therapy. Clinical case description. The results of ustekinumab administration in 12 children with palmoplantar psoriasis are presented. No comorbid pathologies were revealed in these patients during further examination. Thus, genetically engineered biologic therapy with ustekinumab (45 mg subcutaneously according to the recommended treatment regimen) was initiated due to the absence of any contraindications. 58.33% of all patients have achieved lower scores of PASI 90 index 12 weeks after therapy initiation. Conclusion. Management with genetically engineered biologic drugs such as ustekinumab (according to recommended regimen) may be suggested for patients with palmoplantar psoriasis due to its systemic chronic pathological process and lesions of functionally significant areas and in cases when standard external therapy, physical therapy, and classical immunosuppressants lack efficacy, in the absence of contraindications.

вульгарный псориазладонно-подошвенный псориазметотрексатгенно-инженерная биологическая терапияустекинумабpsoriasis vulgarispalmoplantar psoriasismethotrexategenetically engineered biologic therapyustekinumabОтсутствует.Not declared.ReferencesGunter NV, Yap BJM, Chua CLL, Yap WH. Combining Understanding of Immunological Mechanisms and Genetic Variants Toward Development of Personalized Medicine for Psoriasis Patients. Front Genet. 2019;10:395. doi: https://doi.org/10.3389/fgene.2019.00395Gunter NV, Yap BJM, Chua CLL, Yap WH. Combining Understanding of Immunological Mechanisms and Genetic Variants Toward Development of Personalized Medicine for Psoriasis Patients. Front Genet. 2019;10:395. doi: https://doi.org/10.3389/fgene.2019.00395Мурашкин Н.Н., Круглова Л.С., Коваленко Ю.А. и др. Коморбидности псориаза в детском возрасте // Вопросы современной педиатрии. — 2020. — Т. 19. — № 6. — С. 460–467. — doi: https://doi.org/10.15690/vsp.v19i6.2149Murashkin NN, Kruglova LS, Kovalenko IA, et al. Psoriasis Comorbidities in Childhood. Voprosy sovremennoi pediatrii — Current Pediatrics. 2020;19(6):460–467. (In Russ). doi: https://doi.org/10.15690/vsp.v19i6.2149Paller AS, Schenfeld J, Accortt NA, Kricorian G. A retrospective cohort study to evaluate the development of comorbidities, including psychiatric comorbidities, among a pediatric psoriasis population. Pediatr Dermatol. 2019;36(3):290–297. doi: https://doi.org/10.1111/pde.13772Paller AS, Schenfeld J, Accortt NA, Kricorian G. A retrospective cohort study to evaluate the development of comorbidities, including psychiatric comorbidities, among a pediatric psoriasis population. Pediatr Dermatol. 2019;36(3):290–297. doi: https://doi.org/10.1111/pde.13772Damiani G, Bragazzi NL, Karimkhani Aksut C, et al. The Global, Regional, and National Burden of Psoriasis: Results and Insights From the Global Burden of Disease 2019 Study. Front Med (Lausanne). 2021;8:743180. doi: https://doi.org/10.3389/fmed.2021.743180Damiani G, Bragazzi NL, Karimkhani Aksut C, et al. The Global, Regional, and National Burden of Psoriasis: Results and Insights From the Global Burden of Disease 2019 Study. Front Med (Lausanne). 2021;8:743180. doi: https://doi.org/10.3389/fmed.2021.743180Kang BY, O’Haver J, Andrews ID. Pediatric Psoriasis Comorbidities: Screening Recommendations for the Primary Care Provider. J Pediatr Health Care. 2021;35(3):337–350. doi: https://doi.org/10.1016/j.pedhc.2020.12.006Kang BY, O’Haver J, Andrews ID. Pediatric Psoriasis Comorbidities: Screening Recommendations for the Primary Care Provider. J Pediatr Health Care. 2021;35(3):337–350. doi: https://doi.org/10.1016/j.pedhc.2020.12.006Branisteanu DE, Georgescu S, Serban IL, et al. Management of psoriasis in children (Review). Exp Ther Med. 2021;22(6):1429. doi: https://doi.org/10.3892/etm.2021.10864Branisteanu DE, Georgescu S, Serban IL, et al. Management of psoriasis in children (Review). Exp Ther Med. 2021;22(6):1429. doi: https://doi.org/10.3892/etm.2021.10864Elvina M. Pediatric Psoriasis: Clinical Features and Course. Open Acc J Bio Sci. 2020;1(5):207–209. doi: https://doi.org/10.38125/OAJBS.000147Elvina M. Pediatric Psoriasis: Clinical Features and Course. Open Acc J Bio Sci. 2020;1(5):207–209. doi: https://doi.org/10.38125/OAJBS.000147Montes de Oca Pedrosa A, Oakley A, Rogers J, Rangaitaha Epiha M. PASI vs PO-PASI: Patient-Oriented PASI (PO-PASI) is comparable to clinician score PASI. Australas J Dermatol. 2022;63(1):e67–e70. doi: https://doi.org/10.1111/ajd.13738Montes de Oca Pedrosa A, Oakley A, Rogers J, Rangaitaha Epiha M. PASI vs PO-PASI: Patient-Oriented PASI (PO-PASI) is comparable to clinician score PASI. Australas J Dermatol. 2022;63(1):e67–e70. doi: https://doi.org/10.1111/ajd.13738Torrelo A. The use of biologics for childhood psoriasis. J Eur Acad Dermatol Venereol. 2019;33(10):1816. doi: https://doi.org/10.1111/jdv.15855. PMID: 31617632Torrelo A. The use of biologics for childhood psoriasis. J Eur Acad Dermatol Venereol. 2019;33(10):1816. doi: https://doi.org/10.1111/jdv.15855. PMID: 31617632Иванов Р.А., Мурашкин Н.Н. Выживаемость биологической терапии у детей, страдающих псориазом: когортное исследование // Вопросы современной педиатрии. — 2021. — Т. 20. — № 5. — С. 451–458. — doi: https://doi.org/10.15690/vsp.v20i5.2323Ivanov RA, Murashkin NN. Biological Therapy Survivability in Children with Psoriasis: Cohort Study. Voprosy sovremennoi pediatrii — Current Pediatrics. 2021;20(5):451–458. (In Russ). doi: https://doi.org/10.15690/vsp.v20i5.2323Мурашкин Н.Н., Амбарчян Э.Т. Сравнительная оценка эффективности и безопасности ингибиторов TNFα и IL12/23 в терапии псориаза у детей // Педиатрическая фармакология. — 2018. — Т. 15. — № 6. — С. 455–463. — doi: https://doi.org/10.15690/pf.v15i6.1983Murashkin NN, Ambarchian ET. Comparative Evaluation of the Treatment Efficacy and Safety of TNFα and IL12/23 Inhibitors in Children With Psoriasis. Pediatricheskaya farmakologiya — Pediatric pharmacology. 2018;15(6):455–463. (In Russ). doi: https://doi.org/10.15690/pf.v15i6.1983Мурашкин Н.Н., Амбарчян Э.Т., Епишев Р.В. и др. Эффективность и безопасность устекинумаба у детей с бляшечной, эритродермической и ладонно-подошвенной формами псориаза: ретроспективное когортное исследование // Вопросы современной педиатрии. — 2020. — Т. 19. — № 6. — С. 531–537. — doi: https://doi.org/10.15690/vsp.v19i6.2153Murashkin NN, Ambarchian ET, Epishev RV, et al. Ustekinumab Efficacy and Safety in Children with Plaque, Erythrodermic and Palmoplanar Forms of Psoriasis: Retrospective Cohort Study. Voprosy sovremennoi pediatrii — Current Pediatrics. 2020;19(6):531–537. (In Russ). doi: https://doi.org/10.15690/vsp.v19i6.2153Chovatiya R, Silverberg JI. Pathophysiology of Atopic Dermatitis and Psoriasis: Implications for Management in Children. Children (Basel). 2019;6(10):108. doi: https://doi.org/10.3390/children6100108Chovatiya R, Silverberg JI. Pathophysiology of Atopic Dermatitis and Psoriasis: Implications for Management in Children. Children (Basel). 2019;6(10):108. doi: https://doi.org/10.3390/children6100108Aggarwal S, Ghilardi N, Xie MH, et al. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production 215 of interleukin-17. J Biol Chem. 2003;278(3):1910–1914. doi: https://doi.org/10.1074/jbc.M207577200Aggarwal S, Ghilardi N, Xie MH, et al. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production 215 of interleukin-17. J Biol Chem. 2003;278(3):1910–1914. doi: https://doi.org/10.1074/jbc.M207577200Lee E, Trepicchio WL, Oestreicher JL, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med. 2004;199(1):125–130. doi: https://doi.org/10.1084/jem.20030451Lee E, Trepicchio WL, Oestreicher JL, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med. 2004;199(1):125–130. doi: https://doi.org/10.1084/jem.20030451Sun HY, Phan K, Paller AS, Sebaratnam DF. Biologics for pediatric psoriasis: A systematic review and meta-analysis. Pediatr Dermatol. 2022;39(1):42–48. doi: https://doi.org/10.1111/pde.14870Sun HY, Phan K, Paller AS, Sebaratnam DF. Biologics for pediatric psoriasis: A systematic review and meta-analysis. Pediatr Dermatol. 2022;39(1):42–48. doi: https://doi.org/10.1111/pde.14870Paller AS, Siegfried EC, Langley RG, et al. Long-Term Safety and Efficacy of Etanercept in Children and Adolescents with Plaque Psoriasis. J Am Acad Dermatol. 2016;74(2):280–287.e1–e3. doi: https://doi.org/10.1016/j.jaad.2015.09.056Paller AS, Siegfried EC, Langley RG, et al. Long-Term Safety and Efficacy of Etanercept in Children and Adolescents with Plaque Psoriasis. J Am Acad Dermatol. 2016;74(2):280–287.e1–e3. doi: https://doi.org/10.1016/j.jaad.2015.09.056Papp K, Thaçi D, Marcoux D, et al. Efficacy and Safety of Adalimumab Every Other Week versus Methotrexate Once Weekly in Children and Adolescents with Severe Chronic Plaque Psoriasis: a Randomised, Double-Blind, Phase 3 Trial. Lancet. 2017;390(10089):40–49. doi: https://doi.org/10.1016/S0140-6736(17)31189-3Papp K, Thaçi D, Marcoux D, et al. Efficacy and Safety of Adalimumab Every Other Week versus Methotrexate Once Weekly in Children and Adolescents with Severe Chronic Plaque Psoriasis: a Randomised, Double-Blind, Phase 3 Trial. Lancet. 2017;390(10089):40–49. doi: https://doi.org/10.1016/S0140- 6736(17)31189-3Philipp S, Menter A, Nikkels AF, et al. Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in pediatric patients (6 to < 12 years of age): efficacy, safety, pharmacokinetic, and biomarker results from the open-label CADMUS Jr study. Br J Dermatol. 2020;183(4):664–672. doi: https://doi.org/10.1111/bjd.19018Philipp S, Menter A, Nikkels AF, et al. Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in pediatric patients (6 to < 12 years of age): efficacy, safety, pharmacokinetic, and biomarker results from the open-label CADMUS Jr study. Br J Dermatol. 2020;183(4):664–672. doi: https://doi.org/10.1111/bjd.19018Magnolo N, Kingo K, Laquer V, et al. A phase III open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results. J Am Acad Dermatol. 2022;86(1): 122–130. doi: https://doi.org/10.1016/j.jaad.2021.08.066Magnolo N, Kingo K, Laquer V, et al. A phase III open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results. J Am Acad Dermatol. 2022;86(1): 122–130. doi: https://doi.org/10.1016/j.jaad.2021.08.066

The authors declare that there are no conflicts of interest present.